Acalnib 100 mg Capsule
Brand Name: Acalnib
Molecule: Acalabrutinib
Strength: 100 mg
Quantity: 30 Capsules
Form: Capsule
Packaging Type: Bottle
Manufacturer/Marketed By: Hetero Healthcare
Country of Origin: India
Please fill in the details below, and we’ll get back to you as soon as possible
Similar Products:
Description
Acalnib 100 mg Capsule contains Acalabrutinib, a targeted anticancer medicine used to treat certain blood cancers. It helps slow cancer cell growth and disease progression under oncologist supervision.
Benefits
-
Targets cancer-causing B-cell pathways
-
Helps slow tumor growth and spread
-
Can improve progression-free survival
-
Convenient oral capsule formulation
-
Well-established option in modern hematologic oncology
Indications and Usage
Acalnib 100 mg Capsule is indicated for the treatment of:
-
Mantle Cell Lymphoma (MCL) in adults previously treated
-
Chronic Lymphocytic Leukemia (CLL)
-
Small Lymphocytic Lymphoma (SLL)
Treatment must be initiated and supervised by an experienced oncologist.
How it Works
Acalabrutinib selectively inhibits BTK (Bruton Tyrosine Kinase) — a key enzyme required for malignant B-cell growth. By blocking this pathway, it prevents cancer cells from multiplying, helping control disease progression.
Dosage & Administration
-
Typical dose: 100 mg twice daily, or as prescribed
-
Swallow capsule whole with water
-
Take at the same times each day
-
Do not crush, chew, or open capsules
-
Do not skip or double doses
-
Routine blood tests and clinical monitoring required
Use only under oncologist guidance.
Side Effects
Common side effects:
-
Headache
-
Fatigue
-
Diarrhea
-
Muscle or joint pain
-
Bruising or bleeding
Serious side effects:
-
Severe bleeding
-
Serious infections
-
Irregular heartbeat (atrial fibrillation)
-
Secondary cancers
-
Low blood cell counts
Seek medical attention if severe or persistent symptoms occur.
Warning and Precaution
-
Not recommended during pregnancy or breastfeeding
-
Use caution in patients with bleeding, heart, or liver disorders
-
Avoid live vaccines during treatment
-
Increased risk of infections — report fever immediately
-
Inform doctor about blood thinners or other ongoing medications
-
Stop treatment and seek help if allergic symptoms develop
Related Products
Related Posts:
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
FDA Fast-Tracks Plixorafenib for BRAF V600E–Mutated Brain Tumors
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 14, 2026.n n Brain tumors, especially high-grade
READ MORE »April 14, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.